Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA’s decision to hold a July 23-24 ...
In my previous post on Hims & Hers (HIMS), I had said that the company’s growth thesis will be put to the test in 2026 while maintaining my “buy” rating. This was the case as the company had been ...
A pending FDA review of several peptides is giving investors a new growth story for Hims as the company resets its U.S. weight-loss business.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results